TriangleAmivantamab (NCT06116682)
Amivantamab trial for Lung Non-Small Cell Carcinoma (NCT06116682). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with stage IV or recurrent non-small-cell lung cancer with MET amplification, confirmed by the required tissue test. Cancer must have progressed after at least one systemic treatment. Other actionable cancer-gene alterations and previous MET kinase inhibitors exclude entry.
The idea: amivantamab blocks MET and EGFR growth signaling. Patients receive injections under the skin weekly in the first 28-day cycle, then twice per cycle. Researchers assess response, progression, survival and toxicity.
This phase 2 study plans 88 patients. SWOG lists 250 recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.